絞り込み

17696

広告

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

著者 Kawaguchi H , Masuda N , Nakayama T , Aogi K , Anan K , Ito Y , Ohtani S , Sato N , Saji S , Takano T , Tokunaga E , Nakamura S , Hasegawa Y , Hattori M , Fujisawa T , Morita S , Yamaguchi M , Yamashita H , Yamashita T , Yamamoto Y , Yotsumoto D , Toi M ,
Breast Cancer.2019 Dec 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (14view , 0users)

Full Text Sources

Research Materials

Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER+ ABC. The Safari study (UMIN000015168) was a retrospective, multicenter cohort study involving 1072 Japanese patients receiving fulvestrant 500 mg mostly as a second- or later-line endocrine therapy for ER+ ABC. The follow-up data after the Safari study were examined, focusing on any relationship between clinicopathological factors and overall survival (OS) in ER+ ABC patients.
PMID: 31811519 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード